- cafead Jun 03, 2021 at 11:12: AM
via Since winning the first CAR-T approval in the US back in 2017, Novartis has been hard at work expanding the reach of its blockbuster cancer drug Kymriah. Gilead’s Yescarta beat it to the punch in follicular lymphoma (FL) back in March — but now, Novartis says it has new pivotal data that could give its old rival a run for its money.
article source
article source